Leukemia, Myelocytic, Acute

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML

A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)

Randomized Double Cord Blood Transplant Study

Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes

AML Treatment in Untreated Adult Patients

Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)

Trial to Reduce Alloimmunization to Platelets (TRAP)

Infection and Tumour Antigen Cellular Therapy

Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)

Risk-adapted Therapy for Adult Acute Myeloid Leukemia.

Use of the MiCK Assay for Apoptosis in AML

A Phase II Study of Maintenance With Azacitidine in MDS Patients

Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia